Advanced in Dihydropyrimidine Dehydrogenase Deficiency

Stephen P. Ackland

New Lambton Heights, NSW, AU 
Advanced in Dihydropyrimidine Dehydrogenase Deficiency
New Lambton Heights, NSW, AU 
OverviewLocationsClinical Research

Overview

Stephen Ackland practices in New Lambton Heights, Australia. Mr. Ackland is rated as an Advanced expert by MediFind in the treatment of Dihydropyrimidine Dehydrogenase Deficiency. His top areas of expertise are Dihydropyrimidine Dehydrogenase Deficiency, Colorectal Cancer, Adrenal Cancer, and COVID-19.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Dihydropyrimidine Dehydrogenase Deficiency.

Gender
Male

Locations

New Lambton Heights, NSW 2305, Australia
Other Locations
Newcastle, NSW, Australia
New Lambton, NSW, Australia
Callaghan, NSW, Australia
Lake Macquarie Private Hospital, Gateshead, NSW, Australia
Calvary Mater Newcastle
Waratah, NSW 2298, Australia
Camperdown, NSW 1450, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients With Hepatic Metastases From Colorectal Cancer
Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients With Hepatic Metastases From Colorectal Cancer
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Dosage Escalation, Study of Multiple Doses of CAVATAKTM (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors (VLA-X06)
A Phase I, Open-label, Dosage Escalation, Study of Multiple Doses of CAVATAKTM (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors (VLA-X06)
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 1 Less Clinical Trial

42 Total Publications

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
Journal: BMC cancer
Published: September 03, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ackland's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile